---
aliases: [VRTX, Vertex Pharmaceuticals]
---
#actor #biotech #cysticfibrosis #genetherapy #usa #public

**Vertex** — Cystic fibrosis monopoly. ALYFTREK next-gen approved. Gene editing partnerships. CASGEVY (sickle cell).

---

## Why Vertex matters

| Metric | Value |
|--------|-------|
| Ticker | VRTX ([[Nasdaq]]) |
| CF market share | **~90%** |
| Key products | Trikafta, ALYFTREK, CASGEVY |
| Pipeline | Gene editing, pain, kidney |

---

## Cystic fibrosis franchise

| Product | Status | Notes |
|---------|--------|-------|
| **Trikafta** | Market leader | ~$9B revenue |
| **ALYFTREK** | FDA approved 2025 | Next-gen, once-daily |

**ALYFTREK advantage:** Greater sweat chloride reduction vs Trikafta, improved QoL potential.

---

## Gene therapy / editing

### CASGEVY (with [[CRISPR Therapeutics]])
- First CRISPR gene therapy approved
- Sickle cell disease, beta-thalassemia
- One-time curative potential

### CF gene editing partnerships

| Partner | Focus | Value |
|---------|-------|-------|
| [[CRISPR Therapeutics]] | CFTR gene correction | Ongoing |
| Moderna | mRNA + LNP delivery | Multi-year |
| Arbor Biotechnologies | Novel editing proteins | Up to $1.2B |

**Goal:** Treat the ~10% of CF patients who don't respond to modulators.

---

## Pipeline diversification

| Area | Asset | Status |
|------|-------|--------|
| Pain | VX-548 | Phase 3 |
| Kidney | APOL1 | Phase 2 |
| Type 1 diabetes | Cell therapy | Phase 1/2 |

---

## Business model

| Metric | Value |
|--------|-------|
| Gross margin | ~90% |
| CF concentration | High |
| R&D focus | Gene therapy, pain |
| Cash position | Strong |

---

## Investment case

**Bull:**
- CF monopoly with ALYFTREK upgrade
- Gene therapy leadership (CASGEVY)
- Pipeline diversification (pain, kidney)
- Strong cash generation

**Bear:**
- CF concentration risk
- Gene therapy adoption slow
- VX-548 (pain) competitive
- Valuation premium

---


![[vrtx-employees-chart.png]]
*Headcount: 6,400 (2025) — up 4.9% YoY*

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | VRTX |
| Exchange | [[Nasdaq]] |
| Revenue | ~$10B |
| Focus | CF, gene therapy |

---

## Related

- [[Moderna]] — mRNA partner
- [[Biopharma]] — sector

---

## Sources

- [Vertex investor relations](https://investors.vrtx.com/)
- [Vertex ALYFTREK approval](https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-alyftrektm-once-daily-next)

*Created 2026-01-09*
